Autopsy report · NCT04709380

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

“IDMC recommended to terminate the study since Interim analysis showed that the experimental group had significant superiority over the control group in TTP and OS (p\<0.001), meeting the predefined interim analysis endpoints in the study protocol.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 11 months before it stopped.
• 36 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sponsor type

University, hospital or other

Conditions

Radiotherapy; Toripalimab; Sorafenib; Advanced Hepatocellular Carcinoma

Interventions

Radiotherapy plus Toripalimab; Sorafenib

Participants

36

Sites

1

Countries

China

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.